Stargardt disease
MONDO:0019353Stargardt disease, also known as Stargardt 1 (STGD1), is an autosomal recessive form of retinal dystrophy that is usually characterized by a progressive loss of central vision associated with irregular macular and perimacular yellow-white fundus flecks, and a so-called ''beaten bronze'' atrophic central macular lesion.
Also known as: Stargardt 1, fundus flavimaculatus, Stargardt disease 1, Stargardt macular dystrophy, juvenile onset macular degeneration
55 clinical trials for this condition and its sub-types, 33 tagged with Stargardt disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Stargardt disease
-
Stargardt disease 3 3 trials
-
Stargardt disease 4 0 trials
-
Stargardt disease 5 0 trials
-
Promising drug may slow blindness in teens with rare eye disease
Disease control CompletedThis study tested an experimental drug called tinlarebant in 104 teenagers with Stargardt disease, a genetic condition that causes progressive vision loss. The goal was to see if the drug could slow the growth of damage in the back of the eye. Participants took the drug or a plac…
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug aims to slow vision loss in rare eye disease
Disease control CompletedThis study tested an experimental drug called Zimura in 121 people with Stargardt disease, a genetic condition that causes vision loss. Participants received either Zimura injections or a sham procedure. The goal was to see if Zimura could safely slow damage to the retina over 18…
Phase 2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC